List view / Grid view
A new vaccine has shown promise at protecting monkeys and mice from COVID-19, its variants and other coronaviruses.
Researchers have found that a metabolite of remdesivir potentially targets a SARS-CoV-2 protein involved in suppressing the host cell's defence response.
Dmytro Spilka explains why UK biotech companies are receiving increasing levels of investment and why this trend is likely to continue.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
Researchers have produced a computational simulation of the SARS-CoV-2 Spike protein, finding spots that glycans do not cover.
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
Researchers have found that over 80 percent of antibodies target sections of the SARS-CoV-2 Spike protein other than the RBD.
Scientists have developed a 3D lung-on-a-chip model of the distal lung and alveolar structures, enabling the study of COVID-19.
A summit will be held between the UK and CEPI to raise funds for vaccine research and development in a bid to avert future pandemics.
UK Health Secretary Matt Hancock has announced £37 million of funding for genomics and data projects to support the life sciences sector.
Scientists have shown that the SARS-CoV-2 Spike protein can initiate gene expression changes, potentially explaining long COVID symptoms.
A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.
Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.